Shares of Opus Genetics (Nasdaq: IRD) surged 57% to $6.81 in active morning trading after the company reported that all five patients in the first cohort of its early-stage gene therapy trial for inherited blindness showed meaningful vision improvement — with zero serious safety issues. The company announced positive 3- and 6-month results from the low-dose Cohort 1 of its ongoing Phase 1/2 clinical trial evaluating a treatment for BEST1-related retinal diseases. The result transforms Opus from a speculative bet into a company with live human proof that its approach works — at least at the smallest dose.

  • Five-for-Five Efficacy Is Rare, but the Sample Is Tiny. Cohort 1 enrolled five participants, and all five demonstrated clinically meaningful improvement in visual function. In rare-disease gene therapy, a perfect early response rate grabs attention because regulators allow smaller trials. But investors should note this is the low-dose cohort — a higher-dose group still needs to be tested, and durability beyond six months is unknown. The stock's leap prices in a best-case scenario before those questions are answered.

  • FDA Alignment Clears the Regulatory Fog. In August 2026, Opus met with the FDA and aligned on a potential pivotal endpoint based on a specific measure of retinal sensitivity improvement, alongside a patient-reported outcome in a randomized, controlled trial.

The company also aligned with the FDA on Phase 3 and commercial manufacturing requirements, which it expects to complete in early 2027. Having the FDA agree on how to measure success before a pivotal trial begins dramatically lowers the risk of a late-stage regulatory rejection — a common killer for small biotechs.

  • The Cash Is There, but the Burn Is Accelerating. As of June 30, 2026, cash and cash equivalents were $88.8 million, and the company expects existing cash plus potential note funding to support operations into 2029.

R&D expenses rose to $11.2 million from $6.0 million year-over-year. A $155 million financing deal with Oberland Capital backstops the runway, but share count jumped to roughly 83.2 million from 69.9 million at year-end 2025 — meaning today's rally values the company near $566 million, a steep price for a firm with no approved product and quarterly revenue under $1 million.

  • Short Sellers Face a Squeeze. Short interest stood at 10.8 million shares — roughly 14.7% of the float — and had climbed dramatically over the prior year. Today's gap-up likely forced covering, amplifying the move. Whether the stock holds depends on whether Cohort 2 data and 2027 Phase 3 dosing confirm the early promise or expose the limits of a five-patient study.